The Pathology of Scleroderma Vascular Disease

Rheumatic Disease Clinics of North America

Volumn 34, Issue 1, 2008, Pages 41-55

  Fleming, Jo Nadine ^a   Schwartz, Stephen Mark ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHO KINASE INHIBITOR;

APOPTOSIS; ARTERY INTIMA PROLIFERATION; AUTHOR; BLOOD VESSEL; BLOOD VESSEL INJURY; CELL INTERACTION; CONGENITAL BLOOD VESSEL MALFORMATION; HUMAN; HYPOTHESIS; IMMUNE SYSTEM; MICROANGIOPATHY; MODEL; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REVIEW; SCLERODERMA; SMOOTH MUSCLE FIBER; STEM CELL TRANSPLANTATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; CAPILLARIES; HUMANS; SCLERODERMA, SYSTEMIC; TUNICA INTIMA; VASCULAR DISEASES;

EID: 40349108592     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2008.01.001     Document Type: Review

References (91)

1. Varga J., and Korn J.H. Pathogenesis: emphasis on human data. In: Clements P.J., and Furst D.E. (Eds). Systemic sclerosis. 2nd edition (2003), Lippincott Williams & Wilkins, Los Angeles (CA) 63-98
2. Guiducci S., Pignone A., and Mattucci-Cerinic M. Raynaud's phenomenon in systemic sclerosis. In: Clements P.J., and Furst D.E. (Eds). Systemic sclerosis. 2nd edition (2003), Lippincott Williams & Wilkins, Los Angeles (CA) 221-240
3. Handa R., Kumar U., Pandey R.M., et al. Raynaud's phenomenon-a prospective study. Journal, Indian Academy of Clinical Medicine 3 (2002) 35-38
4. von Bierbrauer A., Barth P., Willert J., et al. Electron microscopy and capillaroscopically guided nailfold biopsy in connective tissue diseases: detection of ultrastructural changes of the microcirculatory vessels. Br J Rheumatol 37 (1998) 1272-1278
5. Campbell P.M., and LeRoy E.C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 4 (1975) 351-368
6. Brown G.E., and O'Leary P.A. Skin capillaries in scleroderma. Arch Intern Med 36 (1925) 73-88
7. Norton W.L., Hurd E.R., Lewis D.C., et al. Evidence of microvascular injury in scleroderma and systemic lupus erythematosus: quantitative study of the microvascular bed. J Lab Clin Med 71 (1968) 919-933
8. Toms S.L., and Cooke E.D. A comparison of the functioning of arteriovenous anastomoses in secondary Raynaud's phenomenon and control subjects in response to local hand warming. Int Angiol 14 (1995) 74-79
9. Rodnan G.P., Myerowitz R.L., and Justh G.O. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine (Baltimore) 59 (1980) 393-408
10. Luggen M., Belhorn L., Evans T., et al. The evolution of Raynaud's phenomenon: a longterm prospective study. J Rheumatol 22 (1995) 2226-2232
11. D'Angelo W.A., Fries J.F., Masi A.T., et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46 (1969) 428-440
12. Blann A.D., Illingworth K., and Jayson M.I. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 20 (1993) 1325-1330
13. Schachna L., and Wigley F.M. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 14 (2002) 686-693
14. Kuwana M., Okazaki Y., Yasuoka H., et al. Defective vasculogenesis in systemic sclerosis. Lancet 364 (2004) 603-610
15. Del Papa N., Colombo G., Fracchiolla N., et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 50 (2004) 1296-1304
16. Kahaleh M.B. Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 22 (2004) S19-S23
17. Flavahan N.A., Flavahan S., Mitra S., et al. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 29 (2003) 275-291
18. Prescott R.J., Freemont A.J., Jones C.J., et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166 (1992) 255-263
19. Trotta F., Biagini G., Cenacchi G., et al. Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. Clin Exp Rheumatol 2 (1984) 209-215
20. Joyal F., Choquette D., Roussin A., et al. Evaluation of the severity of systemic sclerosis by nailfold capillary microscopy in 112 patients. Angiology 43 (1992) 203-210
21. Choi J.J., Min D.J., Cho M.L., et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 30 (2003) 1529-1533
22. Distler O., Del Rosso A., Giacomelli R., et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4 (2002) R11
23. Dor Y., Djonov V., and Keshet E. Induction of vascular networks in adult organs: implications to proangiogenic therapy. Ann N Y Acad Sci 995 (2003) 208-216
24. Fleming J.N., Nash R.A., McCleod D.O., et al. Capillary regeneration in scleroderma; stem cell therapy reverses phenotype?. PLoS ONE 3 1 (2008) e1452
25. An S.F., and Fleming K.A. Removal of inhibitor(s) of the polymerase chain reaction from formalin fixed, paraffin wax embedded tissues. J Clin Pathol 44 (1991) 924-927
26. Youssef P., Englert H., and Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis 52 (1993) 464-466
27. Veale D.J., Collidge T.A., and Belch J.J. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54 (1995) 853-855
28. Schwartz S.M. The intima: A new soil. Circ Res 85 (1999) 877-879
29. Korshunov V.A., Schwartz S.M., and Berk B.C. Vascular remodeling: hemodynamic and biochemical mechanisms underlying Glagov's phenomenon. Arterioscler Thromb Vasc Biol 27 (2007) 1722-1728
30. Schwartz S.M., Galis Z.S., Rosenfeld M.E., et al. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol 27 (2007) 705-713
31. Xu Q. Progenitor cells in vascular repair. Curr Opin Lipidol 18 (2007) 534-539
32. Bentzon J.F., Weile C., Sondergaard C.S., et al. Smooth muscle cells in atherosclerosis originate from the local vessel wall and not circulating progenitor cells in ApoE knockout mice. Arterioscler Thromb Vasc Biol 26 12 (2006) 2969-702
33. Torsney E., Hu Y., and Xu Q. Adventitial progenitor cells contribute to arteriosclerosis. Trends Cardiovasc Med 15 (2005) 64-68
34. Liu C., Nath K.A., Katusic Z.S., et al. Smooth muscle progenitor cells in vascular disease. Trends Cardiovasc Med 14 (2004) 288-293
35. Mitchell R.N., and Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 100 (2007) 967-978
36. Rahmani M., Cruz R.P., Granville D.J., et al. Allograft vasculopathy versus atherosclerosis. Circ Res 99 (2006) 801-815
37. Raines E.W. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15 (2004) 237-254
38. Schwartz S.M., Reidy M.A., and de Blois D. Factors important in arterial narrowing. J Hypertens Suppl 14 (1996) S71-S81
39. Charo I.F., and Taubman M.B. Chemokines in the pathogenesis of vascular disease. Circ Res 95 (2004) 858-866
40. Koyama H., Olson N.E., and Reidy M.A. Cell signaling in injured rat arteries. Thromb Haemost 82 (1999) 806-809
41. Llodra J., Angeli V., Liu J., et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 101 (2004) 11779-11784
42. Cheng K.S., Tiwari A., Boutin A., et al. Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology (Oxford) 42 (2003) 1299-1305
43. Guiducci S., Giacomelli R., and Cerinic M.M. Vascular complications of scleroderma. Autoimmun Rev 6 (2007) 520-523
44. Herrick A.L. Vascular function in systemic sclerosis. Curr Opin Rheumatol 12 (2000) 527-533
45. Mulvany M.J. Structural abnormalities of the resistance vasculature in hypertension. J Vasc Res 40 6 (2003) 558-560
46. Kozai T., Shimokawa H., Fukumoto Y., et al. Tyrosine kinase inhibitor markedly suppresses the development of coronary lesions induced by long-term treatment with platelet-derived growth factor in pigs in vivo. J Cardiovasc Pharmacol 29 4 (1997) 536-545
47. Masumoto A., Mohri M., Shimokawa H., et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105 (2002) 1545-1547
48. Kandabashi T., Shimokawa H., Mukai Y., et al. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22 (2002) 243-248
49. Shimokawa H., Morishige K., Miyata K., et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 51 1 (2001) 169-177
50. Fukumoto Y., Mohri M., Inokuchi K., et al. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 49 3 (2007) 117-121
51. Kandabashi T., Shimokawa H., Miyata K., et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 101 11 (2000) 1319-1323
52. Ito A., Shimokawa H., Fukumoto Y., et al. The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo. Cardiovasc Res 32 3 (1996) 570-579
53. Wallez Y., Vilgrain I., and Huber P. Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 16 (2006) 55-59
54. Duan H, Fleming J, Pritchard DK, et al. Combined analysis of monocyte and lymphocyte mRNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum, in press.
55. Angiolillo A.L., Sgadari C., Taub D.D., et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182 (1995) 155-162
56. Cho H., Kozasa T., Bondjers C., et al. Pericyte-specific expression of RGS5: implications for PDGF and EDG receptor signaling during vascular maturation. FASEB J 17 (2003) 440-442
57. Jun J.B., Kuechle M., Harlan J.M., et al. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 15 (2003) 756-760
58. Skurk C., Maatz H., Kim H.S., et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability C through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 279 2 (2004) 1513-1525
59. Schouten M., Wiersinga W.J., Levi M., et al. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol (2007) [epub ahead of print]
60. Winn R.K., and Harlan J.M. The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost 3 8 (2005) 1815-1824
61. Houben A.J., Beljaars J.H., Hofstra L., et al. Microvascular abnormalities in chronic heart failure: a cross-sectional analysis. Microcirculation 10 (2003) 471-478
62. Antonios T.F., Singer D.R., Markandu N.D., et al. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension 34 (1999) 655-658
63. Randolph G.J., Angeli V., and Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5 (2005) 617-628
64. Liu X., Zhu S., Wang T., et al. Paclitaxel modulates TGFß Signaling in scleroderma skin grafts in immunodeficient mice. PLoS Med 2 (2005) e354
65. Shimokawa H., and Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 28 6 (2007) 296-302
66. Sgonc R. The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol 120 (1999) 169-176
67. Sgonc R., Gruschwitz M.S., Dietrich H., et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98 (1996) 785-792
68. Christner P.J., Peters J., Hawkins D., et al. The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 38 (1995) 1791-1798
69. Dodig T.D., Mack K.T., Cassarino D.F., et al. Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum 44 (2001) 723-727
70. Le Hir M., Martin M., and Haas C. A syndrome resembling human systemic sclerosis (scleroderma) in MRL/lpr mice lacking interferon-gamma (IFN-gamma) receptor (MRL/lprgammaR-/-). Clin Exp Immunol 115 (1999) 281-287
71. Zhang Y., and Gilliam A.C. Animal models for scleroderma: an update. Curr Rheumatol Rep 4 (2002) 150-162
72. Sonnylal S., Denton C.P., Zheng B., et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 56 (2006) 334-344
73. Braverman I.M. The cutaneous microcirculation. J Investig Dermatol Symp Proc 5 (2000) 3-9
74. Zhang Y., McCormick L.L., Desai S.R., et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168 (2002) 3088-3098
75. Ruzek M.C., Jha S., Ledbetter S., et al. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 50 (2004) 1319-1331
76. Jaffee B.D., and Claman H.N. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol 77 (1983) 1-12
77. Andrews M.L., Robertson I., and Weedon D. Cutaneous manifestations of chronic graft-versus-host disease. Australas J Dermatol 38 (1997) 53-62
78. Farmer E.R. Human cutaneous graft-versus-host disease. J Invest Dermatol 85 (1985) 124s-128s
79. Aractingi S., and Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol 134 (1998) 602-612
80. Biedermann B.C., Sahner S., Gregor M., et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 359 (2002) 2078-2083
81. Ertault-Daneshpouy M., Leboeuf C., Lemann M., et al. Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease. Blood 103 (2004) 4681-4684
82. Hillebrands J.L., Klatter F.A., and Rozing J. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 380-387
83. Weis M., and von Scheidt W. Cardiac allograft vasculopathy a review. Circulation 96 (1997) 2069-2077
84. Karnovsky M.J., Russell M.E., Hancock W., et al. Chronic rejection in experimental cardiac transplantation in a rat model. Clin Transplant 8 (1994) 308-312
85. Hruban R.H., Beschorner W.E., Baumgartner W.A., et al. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. Am J Pathol 137 (1990) 871-882
86. Denton M.D., Davis S.F., Baum M.A., et al. The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. Pediatr Transplant 4 (2000) 252-260
87. Koglin J., and Russell M.E. Alloimmune-mediated apoptosis: comparison in mouse models of acute and chronic cardiac rejection. Transplantation 67 (1999) 904-909
88. Crisp S.J., Dunn M.J., Rose M.L., et al. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease?. J Heart Lung Transplant 13 (1994) 81-91
89. Mulligan-Kehoe M.J., Drinane M.C., Mollmark J., et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 56 (2007) 3448-3458
90. Sata M. Role of circulating vascular progenitors in angiogenesis, vascular healing, andpulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol 26 (2006) 1008-1014
91. Goldschmidt-Clermont P.J. Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis. Am Heart J 146 (2003) S5-S12